Financing ·
Clearmind Medicine to issue $2M convertible notes at a 90% discount for $1.8M cash
CMNDClearmind Medicine Inc.
On October 16, 2026, Clearmind Medicine Inc. delivered notice to the CLA Investors to issue and sell convertible promissory notes with an aggregate principal amount of $2,000,000. The company will receive an aggregate purchase price of $1,800,000 in cash, representing 90% of the principal amount. The transaction is expected to close on or before October 19, 2026. This issuance is part of a broader amendment dated April 30, 2026, which authorized the sale of up to $10,000,000 in convertible promissory notes under existing securities purchase agreements. Clearmind Medicine Inc. operates in the biotechnology industry, focusing on the development of novel therapeutics for neurological and psychiatric disorders.